Notably, Asian subgroup analyses revealed a significantly higher ORR of 50% (9), potentially attributable to molecular subtypes of HER2-positive gastric cancer (e.g., higher prevalence of intestinal-type per Lauren classification) and pharmacogenetic variations. Here, ERBB2 is linked to gastric cancer.